New pharmacological therapies for the treatment of copd: a review of long-acting muscarinic agonists and long-acting beta-agonists
DOI:
https://doi.org/10.59471/ijhsc202497Keywords:
COPD, treatment, long-acting muscarinic receptors, long – acting beta-agonists, LABA, LAMAAbstract
Chronic obstructive pulmonary disease (COPD) is characterized by obstruction of the air outlet from the lungs. It is currently recognized as a systemic disease that may be related to other conditions such as cardiovascular and metabolic diseases and cancer. The main treatment of COPD consists of the use of inhaled bronchodilator medications such as long- acting muscarinic antagonists (LAMA) and long- acting beta-agonists (LABA) to improve symptoms and quality of life. At the moment there is no conclusive answer about which is the superior option between LAMA and LABA in the treatment of COPD, however, it is possible to use a combination of both types of drugs, the selection of a particular treatment will depend on various factors, such as disease severity, individual symptoms, response to treatment, and patient preferences.
Published
Issue
Section
License
Copyright (c) 2024 Edisson Vladimir Maldonado Mariño, Alex Mauricio Medina Aldaz, Diego Eduardo Guato Canchinia, Diego Armando Suarez Páez (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
